EHA 2022 | Panobinostat for the treatment of myeloma and relevance in the UK
Rakesh Popat
• 10 Jun 2022
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, briefly discusses the role of panobinostat in myeloma treatment and relevance in the UK. Dr Popat comments on the benefit of combining panobinostat with bortezomib and dexamethasone in certain patient populations, and further highlights factors and adverse events (AEs) to consider when using this agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
